Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 5536 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1665    
    Printed31    
    Emailed0    
    PDF Downloaded406    
    Comments [Add]    

Recommend this journal

 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 59  |  Issue : 4  |  Page : 451-456

Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium


1 Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India
2 Department of General Medicine, Government Medical College and Hospital, Chandigarh, India

Correspondence Address:
Dr. Ajeet Sidana
Department of Psychiatry, Government Medical College and Hospital, Sector-32, Chandigarh (UT) - 160 030
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/psychiatry.IndianJPsychiatry_59_17

Rights and Permissions

Objective: Till date, typical antipsychotic haloperidol is the treatment of choice for delirium. But, due to higher side effects with haloperidol, newer atypical antipsychotics (e.g., olanzapine) are increasingly being used in the treatment of delirious patients. The aim of the current research was to study the efficacy and tolerability of haloperidol and olanzapine in the treatment of delirium. Materials and Methods: This was an open-label, randomized controlled study carried out in a tertiary care hospital at Chandigarh, India. A total of 100 patients admitted in medicine, surgery, and orthopedic wards and diagnosed as having delirium on Confusion Assessment Method scale were included in the study. Patients were given either haloperidol (1–4 mg/day either orally or by nasogastric tube) or olanzapine (2.5–10 mg/day either orally or by nasogastric tube). Severity of delirium and pattern of symptom improvement were assessed by Memorial Delirium Assessment Scale (MDAS). Extrapyramidal side effects were assessed by Simpson–Angus Scale. Results: There was an improvement in delirium severity in both groups with treatment. Mean daily dose of haloperidol and olanzapine used per patient was 2.10 and 5.49 mg, respectively, and the mean duration of treatment in olanzapine group and haloperidol group was 3.57 days and 3.37 days, respectively. There was no significant difference in the mean duration of treatment in both groups. At the end of study period, the MDAS scores in olanzapine and haloperidol groups were 8.43 and 8.00, respectively, and the difference was not significant statistically with P = 0.765. Five patients experienced drug-related mild side effects. Conclusion: Low-dose haloperidol and olanzapine were equally efficacious and well tolerated in delirium.



[FULL TEXT] [PDF]*

        

Print this article         Email this article